GADOLIN: Combination improves PFS in rituximab-refractory indolent NHL

CHICAGO – Progression-free survival for patients with rituximab-refractory indolent non-Hodgkin’s lymphoma was effectively doubled with a combination of obinutuzumab and bendamustine, compared with...